Compassionate Use of REGN-COV2 for the Treatment of COVID-19
Status
Conditions
COVID-19
Treatments
Drug: REGN10933+REGN10987 combination therapy
Details and patient eligibility
About
Compassionate Use requests will be considered for individuals who test positive for SARS-CoV-2 and where there is reasonable basis to believe that the patient is infected with a susceptible variant.
Full description
Compassionate Use requests are only being considered in response to Individual Patient Investigational New Drug (IND) applications.
Sex
Volunteers
No Healthy Volunteers
Inclusion and exclusion criteria
Trial contacts and locations
0
Loading...
Central trial contact
Requests for compassionate use must be initiated by a treating physician. Physicians should contact
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal
© Copyright 2026 Veeva Systems